SI2643352T1 - Antigen-vezavni proteini na onkostatin M (OSM) - Google Patents

Antigen-vezavni proteini na onkostatin M (OSM)

Info

Publication number: SI2643352T1
Authority: SI; Slovenia
Prior art keywords: oncostatin; osm; antigen binding; binding proteins; proteins
Prior art date: 2010-11-23

Application number

SI201131537T

Other languages

English (en)

Inventor

Gary Peter Bembridge

Chun-Wa Chung

Maria Feeney

Susannah Karen Ford

Ian Kirby

Ruth Mcadam

Original Assignee

Glaxo Group Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-11-23

Filing date

2011-11-21

Publication date

2018-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45001764&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2643352(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-11-21 Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited

2018-12-31 Publication of SI2643352T1 publication Critical patent/SI2643352T1/sl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Investigating Or Analysing Biological Materials (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Measuring Volume Flow (AREA)

SI201131537T 2010-11-23 2011-11-21 Antigen-vezavni proteini na onkostatin M (OSM) SI2643352T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US41649510P	2010-11-23	2010-11-23
PCT/EP2011/070604 WO2012069433A2 (en)	2010-11-23	2011-11-21	Antigen binding proteins
EP11785424.0A EP2643352B1 (en)	2010-11-23	2011-11-21	Antigen binding proteins to oncostatin m (osm)

Publications (1)

Publication Number	Publication Date
SI2643352T1 true SI2643352T1 (sl)	2018-12-31

Family

ID=45001764

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI201131537T SI2643352T1 (sl)	2010-11-23	2011-11-21	Antigen-vezavni proteini na onkostatin M (OSM)

Country Status (38)

Country	Link
US (4)	US8916695B2 (sl)
EP (3)	EP3211009A1 (sl)
JP (2)	JP6351973B2 (sl)
KR (2)	KR101947356B1 (sl)
CN (1)	CN103328508B (sl)
AR (1)	AR083937A1 (sl)
AU (1)	AU2011333878B2 (sl)
BR (1)	BR112013012627A2 (sl)
CA (1)	CA2818534A1 (sl)
CL (1)	CL2013001466A1 (sl)
CO (1)	CO6801627A2 (sl)
CY (1)	CY1120448T1 (sl)
DK (1)	DK2643352T3 (sl)
DO (1)	DOP2013000113A (sl)
EA (1)	EA027256B1 (sl)
ES (1)	ES2681949T3 (sl)
HR (1)	HRP20181092T1 (sl)
HU (1)	HUE039412T2 (sl)
IL (1)	IL226157B (sl)
JO (1)	JO3455B1 (sl)
LT (1)	LT2643352T (sl)
MA (1)	MA34742B1 (sl)
ME (1)	ME03069B (sl)
MX (1)	MX351887B (sl)
MY (1)	MY170404A (sl)
NZ (1)	NZ610464A (sl)
PE (1)	PE20140519A1 (sl)
PL (1)	PL2643352T3 (sl)
PT (1)	PT2643352T (sl)
RS (1)	RS57502B1 (sl)
SG (2)	SG190232A1 (sl)
SI (1)	SI2643352T1 (sl)
TR (1)	TR201810773T4 (sl)
TW (1)	TWI504609B (sl)
UA (1)	UA111954C2 (sl)
UY (1)	UY33743A (sl)
WO (1)	WO2012069433A2 (sl)
ZA (1)	ZA201303541B (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6216917B2 (ja)	2010-10-13	2017-10-25	ヤンセンバイオテツク，インコーポレーテツド	ヒトオンコスタチンｍ抗体及び使用方法
SG190232A1 (en)	2010-11-23	2013-06-28	Glaxo Group Ltd	Antigen binding proteins to oncostatin m (osm)
US9550828B2 (en)	2013-09-05	2017-01-24	Boise State University	Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
EP3197480A1 (en)	2014-09-24	2017-08-02	Universita' Degli Studi Di Padova	Composition to induce bone marrow stem cell mobilization
CN107530431B (zh) *	2015-01-29	2022-01-07	牛津大学创新有限公司	生物标志物
GB201614627D0 (en) *	2016-08-30	2016-10-12	Glaxosmithkline Ip Dev Ltd	Antigen binding proteins
FR3090637A1 (fr) *	2018-12-21	2020-06-26	Universite De Poitiers	Protéine de liaison spécifique capable de se lier spécifiquement à l’oncostatine M humaine (hOSM) et ses utilisations.
US11633457B2 (en)	2019-04-11	2023-04-25	Boise State University	Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS57106673A (en)	1980-12-24	1982-07-02	Chugai Pharmaceut Co Ltd	Dibenzo(b,f)(1,4)oxazepin derivative
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4666884A (en)	1984-04-10	1987-05-19	New England Deaconess Hospital	Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
US4873316A (en)	1987-06-23	1989-10-10	Biogen, Inc.	Isolation of exogenous recombinant proteins from the milk of transgenic mammals
WO1991014438A1 (en)	1990-03-20	1991-10-03	The Trustees Of Columbia University In The City Of New York	Chimeric antibodies with receptor binding ligands in place of their constant region
AU4116793A (en)	1992-04-24	1993-11-29	Board Of Regents, The University Of Texas System	Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5783672A (en) *	1994-05-26	1998-07-21	Immunex Corporation	Receptor for oncostatin M
GB9424449D0 (en)	1994-12-02	1995-01-18	Wellcome Found	Antibodies
US5747035A (en)	1995-04-14	1998-05-05	Genentech, Inc.	Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US6096871A (en)	1995-04-14	2000-08-01	Genentech, Inc.	Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997043316A1 (en)	1996-05-10	1997-11-20	Beth Israel Deaconess Medical Center, Inc.	Physiologically active molecules with extended half-lives and methods of using same
DE19742706B4 (de)	1997-09-26	2013-07-25	Pieris Proteolab Ag	Lipocalinmuteine
US5958442A (en) *	1997-10-24	1999-09-28	Bristol-Myers Squibb Company	Oncostatin M for treating inflammation
WO1999043713A1 (en)	1998-02-25	1999-09-02	Lexigen Pharmaceuticals Corporation	Enhancing the circulating half-life of antibody-based fusion proteins
GB9806530D0 (en) *	1998-03-26	1998-05-27	Glaxo Group Ltd	Inflammatory mediator
GB9809839D0 (en)	1998-05-09	1998-07-08	Glaxo Group Ltd	Antibody
EP1105427A2 (en)	1998-08-17	2001-06-13	Abgenix, Inc.	Generation of modified molecules with increased serum half-lives
IL127127A0 (en)	1998-11-18	1999-09-22	Peptor Ltd	Small functional units of antibody heavy chain variable regions
US6818418B1 (en)	1998-12-10	2004-11-16	Compound Therapeutics, Inc.	Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en)	1998-12-10	2006-10-03	Compound Therapeutics, Inc.	Protein scaffolds for antibody mimics and other binding proteins
PL209786B1 (pl)	1999-01-15	2011-10-31	Genentech Inc	Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
DK2275540T3 (en)	1999-04-09	2016-05-09	Kyowa Hakko Kirin Co Ltd	Method for controlling the activity of immunologically functional molecule.
US7504256B1 (en)	1999-10-19	2009-03-17	Kyowa Hakko Kogyo Co., Ltd.	Process for producing polypeptide
ES2298106T3 (es) *	2000-04-21	2008-05-16	Conaris Research Institute Ag	Proteinas de fusion que comprenden dos moleculas gp130 solubles.
DK1332209T3 (da)	2000-09-08	2010-03-29	Univ Zuerich	Samlinger af repeatproteiner indeholdende repeatmoduler
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6374470B1 (en)	2000-10-06	2002-04-23	Milliken & Company	Face plate for spun-like textured yarn
ATE489395T1 (de)	2000-12-12	2010-12-15	Medimmune Llc	Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
MXPA05000511A (es) *	2001-07-12	2005-09-30	Jefferson Foote	Anticuepros super humanizados.
KR20040054669A (ko)	2001-08-03	2004-06-25	글리카트 바이오테크놀로지 아게	항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체
US20050043519A1 (en)	2001-08-10	2005-02-24	Helen Dooley	Antigen binding domains
ATE416190T1 (de)	2003-07-04	2008-12-15	Affibody Ab	Polypeptide mit bindungsaffinität für her2
WO2005019255A1 (en)	2003-08-25	2005-03-03	Pieris Proteolab Ag	Muteins of tear lipocalin
PE20090046A1 (es) *	2003-11-10	2009-01-26	Schering Corp	Anticuerpo recombinante humanizado anti-interleuquina 10
BRPI0417302A (pt)	2003-12-05	2007-03-06	Compound Therapeutics Inc	inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
WO2005095457A2 (en) *	2004-03-30	2005-10-13	Glaxo Group Limited	Immunoglobulins
GB0407197D0 (en) *	2004-03-30	2004-05-05	Glaxo Group Ltd	Immunoglobulins
CA2573745A1 (en)	2004-07-21	2007-01-12	Glycofi, Inc.	Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform
US7923538B2 (en)	2005-07-22	2011-04-12	Kyowa Hakko Kirin Co., Ltd	Recombinant antibody composition
AU2006270718B2 (en)	2005-07-22	2011-07-21	Kyowa Kirin Co., Ltd.	Genetically modified antibody composition
PE20080262A1 (es) *	2006-05-25	2008-04-30	Glaxo Group Ltd	Anticuerpo humanizado contra interleuquina-18
EP1958957A1 (en)	2007-02-16	2008-08-20	NascaCell Technologies AG	Polypeptide comprising a knottin protein moiety
WO2010056893A1 (en) *	2008-11-13	2010-05-20	Imclone Llc	Humanization and affinity-optimization of antibodies
JP6216917B2 (ja) *	2010-10-13	2017-10-25	ヤンセンバイオテツク，インコーポレーテツド	ヒトオンコスタチンｍ抗体及び使用方法
SG190232A1 (en)	2010-11-23	2013-06-28	Glaxo Group Ltd	Antigen binding proteins to oncostatin m (osm)

2011
- 2011-11-21 SG SG2013035951A patent/SG190232A1/en unknown
- 2011-11-21 WO PCT/EP2011/070604 patent/WO2012069433A2/en active Application Filing
- 2011-11-21 MY MYPI2013700832A patent/MY170404A/en unknown
- 2011-11-21 SG SG10201500388PA patent/SG10201500388PA/en unknown
- 2011-11-21 CA CA2818534A patent/CA2818534A1/en not_active Abandoned
- 2011-11-21 TR TR2018/10773T patent/TR201810773T4/tr unknown
- 2011-11-21 BR BR112013012627A patent/BR112013012627A2/pt not_active Application Discontinuation
- 2011-11-21 PE PE2013001238A patent/PE20140519A1/es active IP Right Grant
- 2011-11-21 PT PT117854240T patent/PT2643352T/pt unknown
- 2011-11-21 PL PL11785424T patent/PL2643352T3/pl unknown
- 2011-11-21 NZ NZ610464A patent/NZ610464A/en not_active IP Right Cessation
- 2011-11-21 DK DK11785424.0T patent/DK2643352T3/en active
- 2011-11-21 ME MEP-2018-182A patent/ME03069B/me unknown
- 2011-11-21 JO JOP/2011/0353A patent/JO3455B1/ar active
- 2011-11-21 UY UY0001033743A patent/UY33743A/es not_active Application Discontinuation
- 2011-11-21 EP EP17166131.7A patent/EP3211009A1/en not_active Withdrawn
- 2011-11-21 RS RS20180819A patent/RS57502B1/sr unknown
- 2011-11-21 AU AU2011333878A patent/AU2011333878B2/en active Active
- 2011-11-21 EA EA201390537A patent/EA027256B1/ru not_active IP Right Cessation
- 2011-11-21 UA UAA201305873A patent/UA111954C2/uk unknown
- 2011-11-21 LT LTEP11785424.0T patent/LT2643352T/lt unknown
- 2011-11-21 SI SI201131537T patent/SI2643352T1/sl unknown
- 2011-11-21 EP EP18163940.2A patent/EP3369744A1/en not_active Withdrawn
- 2011-11-21 CN CN201180065512.0A patent/CN103328508B/zh active Active
- 2011-11-21 ES ES11785424.0T patent/ES2681949T3/es active Active
- 2011-11-21 KR KR1020187027871A patent/KR101947356B1/ko active IP Right Grant
- 2011-11-21 US US13/989,191 patent/US8916695B2/en active Active
- 2011-11-21 HU HUE11785424A patent/HUE039412T2/hu unknown
- 2011-11-21 AR ARP110104328A patent/AR083937A1/es unknown
- 2011-11-21 MX MX2013005843A patent/MX351887B/es active IP Right Grant
- 2011-11-21 KR KR1020137016213A patent/KR20130119948A/ko active Application Filing
- 2011-11-21 JP JP2013539295A patent/JP6351973B2/ja active Active
- 2011-11-21 TW TW100142577A patent/TWI504609B/zh not_active IP Right Cessation
- 2011-11-21 EP EP11785424.0A patent/EP2643352B1/en active Active
2013
- 2013-05-05 IL IL226157A patent/IL226157B/en active IP Right Grant
- 2013-05-15 ZA ZA2013/03541A patent/ZA201303541B/en unknown
- 2013-05-17 CO CO13122422A patent/CO6801627A2/es unknown
- 2013-05-21 DO DO2013000113A patent/DOP2013000113A/es unknown
- 2013-05-23 CL CL2013001466A patent/CL2013001466A1/es unknown
- 2013-06-19 MA MA36018A patent/MA34742B1/fr unknown
2014
- 2014-11-13 US US14/540,247 patent/US9605063B2/en active Active
2016
- 2016-11-11 JP JP2016220093A patent/JP2017078072A/ja active Pending
2017
- 2017-02-09 US US15/428,528 patent/US10808029B2/en active Active
2018
- 2018-07-11 HR HRP20181092TT patent/HRP20181092T1/hr unknown
- 2018-07-24 CY CY20181100770T patent/CY1120448T1/el unknown
2020
- 2020-07-09 US US16/924,628 patent/US20210017270A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CO6801627A2 (es)	2013-11-29
US20130251724A1 (en)	2013-09-26
BR112013012627A2 (pt)	2016-10-04
EP3211009A1 (en)	2017-08-30
JP6351973B2 (ja)	2018-07-04
CN103328508A (zh)	2013-09-25
IL226157B (en)	2020-10-29
RS57502B1 (sr)	2018-10-31
IL226157A0 (en)	2013-06-27
MX2013005843A (es)	2013-07-05
EP2643352A2 (en)	2013-10-02
MX351887B (es)	2017-11-01
SG10201500388PA (en)	2015-03-30
MY170404A (en)	2019-07-27
SG190232A1 (en)	2013-06-28
UY33743A (es)	2012-06-29
MA34742B1 (fr)	2013-12-03
WO2012069433A2 (en)	2012-05-31
US10808029B2 (en)	2020-10-20
PE20140519A1 (es)	2014-04-30
CL2013001466A1 (es)	2014-06-27
NZ610464A (en)	2015-02-27
TWI504609B (zh)	2015-10-21
US20150064201A1 (en)	2015-03-05
AR083937A1 (es)	2013-04-10
JO3455B1 (ar)	2020-07-05
AU2011333878B2 (en)	2016-01-14
US20210017270A1 (en)	2021-01-21
KR101947356B1 (ko)	2019-02-12
EA027256B1 (ru)	2017-07-31
PL2643352T3 (pl)	2018-10-31
ZA201303541B (en)	2014-11-26
ES2681949T3 (es)	2018-09-17
DK2643352T3 (en)	2018-07-30
PT2643352T (pt)	2018-08-01
JP2017078072A (ja)	2017-04-27
EA201390537A1 (ru)	2014-01-30
JP2014507373A (ja)	2014-03-27
EP2643352B1 (en)	2018-05-02
LT2643352T (lt)	2018-08-10
CA2818534A1 (en)	2012-05-31
WO2012069433A3 (en)	2012-08-09
US20170152312A1 (en)	2017-06-01
TR201810773T4 (tr)	2018-08-27
CN103328508B (zh)	2015-12-16
KR20130119948A (ko)	2013-11-01
DOP2013000113A (es)	2013-12-15
ME03069B (me)	2019-01-20
TW201235358A (en)	2012-09-01
EP3369744A1 (en)	2018-09-05
US8916695B2 (en)	2014-12-23
UA111954C2 (uk)	2016-07-11
HRP20181092T1 (hr)	2018-09-21
CY1120448T1 (el)	2019-07-10
AU2011333878A1 (en)	2013-05-09
KR20180110199A (ko)	2018-10-08
US9605063B2 (en)	2017-03-28
HUE039412T2 (hu)	2018-12-28

Publication	Publication Date	Title
HUS1900048I1 (hu)	2019-11-28	Anti-IL-23 antitestek
HRP20181092T1 (hr)	2018-09-21	Antigenski vežući proteini koji djeluju na onkostatin m (osm)
SG10201401681PA (en)	2014-07-30	Novel antigen binding proteins
HK1199042A1 (en)	2015-06-19	Cd27l antigen binding proteins cd27l
ZA201208906B (en)	2014-05-28	Humanised antigen binding proteins to myostatin6
EP2681239B8 (en)	2015-09-09	Antigen binding proteins
HK1170506A1 (en)	2013-03-01	Bispecific antigen binding proteins
EP2744517A4 (en)	2015-04-22	COMPOSITIONS AND METHODS RELATED TO STAPHYLOCOCCAL ANTI-PROTEIN ANTIBODIES
HK1213905A1 (zh)	2016-07-15	受體結合蛋白
ZA201205624B (en)	2014-01-29	Cd127 binding proteins